Company intelligence / Profile preview

TransPharma Medical Ltd.

Lod, Israel

Ownership: Private
Development stage: Other

Overview

TransPharma Medical developed a proprietary active transdermal drug delivery platform and advanced several programs into early clinical development. The ViaDerm/GLP‑1 agonist completed a Phase I trial by September 2010. An insulin patch was also in development for diabetes. There are no recent published results or late-stage data available.

Therapeutic areas: Endocrinology
Modalities: transdermal drug delivery (including peptides, proteins, small molecules)radio-frequency microchannel technology for transdermal delivery
Industry: Biotech

Drug pipeline

1 asset

ViaDerm-hGH

Discontinued

Partnerships

Teva Pharmaceuticals – joint development agreement on RF-MicroChannels™ technology since at least 2004, with milestone payments reported in 2006Eli Lilly – licensing/development partnership announced circa 2008–2010 regarding teriparatide patch project

Beyond the preview

Go deeper on TransPharma Medical Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TransPharma Medical Ltd..